Diversity in Alzheimer's disease drug trials: The importance of eligibility criteria

2021118 citationsReviewhybrid Open Access

Authors

Sanne Franzen · Erasmus MC

Jade Emily Smith · Erasmus MC

Esther van den Berg · Erasmus MC

Mónica Rivera Mindt · Fordham University

Rozemarijn L van Bruchem-Visser · Erasmus MC

Erin L. Abner · Kentucky Department for Public Health

Lon S. Schneider ·

Abstract

Ethnoracially diverse participants continue to be underrepresented in AD clinical trials. Several recommendations are provided to broaden eligibility criteria.

Topics & Keywords

Health Systems, Economic Evaluations, Quality of Life Pharmaceutical Economics and Policy Ethics in Clinical Research

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: Alzheimer s & Dementia

Volume 18, Issue 4, pp. 810-823

DOI: 10.1002/alz.12433

Field-Weighted Citation Impact: 23.38